Company Overview and News


Add SGEN
to your dashboard

Headline News

Time to Buy PRIMECAP Odyssey Growth Fund (POGRX)

19h zacks
PRIMECAP Odyssey Growth Fund (POGRX - Free Report) seeks capital appreciation. POGRX normally invests in common stocks of U.S. companies that possess high earnings growth. POGRX may invest in companies from different sectors and diverse market-cap. (62-0)

IMMU / Immunomedics, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2017-11-15 fintel.io
Immunomedics, Inc. (NASDAQ:IMMU) has 166 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 130,271,376 shares. Largest shareholders include venBio Select Advisor LLC, Seattle Genetics Inc /wa, Orbimed Advisors Llc, BlackRock Inc., and Acuta Capital Partners, Llc. (62-0)

Seattle Genetics' Adcetris Gets FDA Nod for Label Expansion

2017-11-13 zacks
Seattle Genetics, Inc. (SGEN - Free Report) announced the FDA approved an expanded indication for its lymphoma drug, Adcetris (brentuximab vedotin). (105-0)

Market Wisdom From A Bioscience Expert - An Integrated BioSci Interview

2017-11-12 seekingalpha
With recent CAR-T approval, TC believes that the Kite Pharma Acquisition added significant value to Gilead Sciences. (242-10)

Your Daily Pharma Scoop: Neurocrine Has Upside, Dynavax Gets FDA Nod, Sage Soars

2017-11-12 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (340-3)

Genmab's (GNMSF) CEO Jan van de Winkel on Q3 2017 Results - Earnings Call Transcript

2017-11-11 seekingalpha
Good day, and welcome to the Quarter Three Report 2017 Conference Call. Today's conference is being recorded. During this telephone conference, you may be presented with forward-looking statements that include words such as belief, anticipate, plans or expects. Actual results may differ materially, for example, as a result of delayed or unsuccessful development projects. Genmab is not under any obligation to update statements regarding the future not to confirm such statements in relation to actual results, unless this is required by law. (4-0)

Immunomedics' (IMMU) Q1 2018 Results - Earnings Call Transcript

2017-11-10 seekingalpha
Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to Immunomedics Incorporated First Quarter Fiscal 2018 Results Conference Call. As a reminder, this call is being recorded. Today is Thursday, November 9, 2017. (58-0)

BRIEF-SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS (BRENTUXIMAB VEDOTIN)

2017-11-09 reuters
* SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA (PCALCL) AND CD30-EXPRESSING MYCOSIS FUNGOIDES (MF) (4-0)

Your Daily Pharma Scoop: Progenics Looks Promising, Big Week For Dynavax, Keryx Ahead Of Catalyst

2017-11-06 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (692-4)

Earnings Review and Free Research Report: Biogen’s Adjusted EPS Surged 25.1%

2017-11-02 accesswire
LONDON, UK / ACCESSWIRE / November 2, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Biogen Inc. (NASDAQ: BIIB), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=BIIB, following the Company's posting of its financial results on October 24, 2017, for the third quarter of the fiscal year 2017. The biotechnology Company's total revenue increased 4% on a y-o-y basis, and was ahead of market expectations. (69-0)

Your Daily Pharma Scoop: Gilead In NASH, Geron Gets A Boost, AstraZeneca's Oncology Portfolio

2017-11-01 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Please click here or scroll down below to read an important announcement about changes and additions to the daily scoop. (498-1)

Paper: GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study

2017-11-01 ash.confex
Daniel J. DeAngelo, MD, PhD1, Brian A Jonas, MD, PhD2, Jane L. Liesveld, MD3, Dale L. Bixby4*, Anjali S. Advani, MD5, Paula Marlton, MBBS6, Michael O'Dwyer, MD7, John L Magnani, PhD8, Helen M. Thackray, MD8 and Pamela S. Becker, MD, PhD9 (45-0)

Featured Company News - FDA Granted Orphan Drug Designation to Merrimack's MM-121 for Treatment of Heregulin Positive Non-Small Cell Lung Cancer

2017-11-01 accesswire
LONDON, UK / ACCESSWIRE / November 1, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) ("Merrimack"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=MACK. The Company announced on October 30, 2017, that the US Food and Drug Administration (FDA) has granted orphan drug designation to MM-121, its investigational drug candidate, for the treatment of heregulin positive non-small cell lung cancer. (39-0)

Your Daily Pharma Scoop: Portola's PDUFA, PDLI Makes Some Money, GWPH Completes Rolling NDA

2017-10-31 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Please click here or scroll down below to read an important announcement about changes and additions to the daily scoop. (765-3)

Your Daily Pharma Scoop: Gilead's Unappreciated Opportunity, Merck's Keytruda Stumble, Epizyme's Positive Results

2017-10-30 seekingalpha
Epizyme’s tazemetostat showed positive results in pediatric patients with relapsed or refractory INI1-negative molecularly defined solid tumors. (509-1)

CUSIP: 812578102